[at Barrons.com] – If news about the biotech sector grabbed your attention yesterday, the saga continues as investors and some analysts are standing by the sector despite yesterday’s downgrade by Goldman Sachs. One winner this afternoon is Celgene (CELG) with shares up 1.3% following yesterday’s 4.2% drop. We recapped the highlights from yesterday in a Barron’s Take after Goldman downgraded the biotech sector and Celgene was cut to Sell from Neutral by the … [visit site to read more]
Company Update – Celgene Corporation (NASDAQ:CELG) – Celgene Gets Infusion from Investors, Analysts Following Goldman Downgrade
January 07, 2014 at 15:31 PM EST
[at Barrons.com] – If news about the biotech sector grabbed your attention yesterday, the saga continues as investors and some analysts are standing by the sector despite yesterday’s downgrade by Goldman Sachs. One . . . → Read More: Company Update – Celgene Corporation (NASDAQ:CELG) – Celgene Gets Infusion from Investors, Analysts Following Goldman Downgrade
